| Capivasertib studied in …STUDIED_INderived55 of 55show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 55 trials list this drug (31 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04493853Phase 3 · active not recruiting Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency · 55 trials list this drug (31 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07343960Phase 1 · recruiting A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02208375Phase 1 · active not recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian · 55 trials list this drug (31 active) | — | — | Breast Carcinoma,Primary Peritoneal Carcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07287917Phase 1/Phase 2 · recruiting Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors · 55 trials list this drug (31 active) | — | — | Breast Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06982521Phase 3 · recruiting Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer · 55 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02523014Phase 2 · recruiting Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas · 55 trials list this drug (31 active) | — | — | Meningioma,Intracranial Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03660826Phase 2 · active not recruiting Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · 55 trials list this drug (31 active) | — | — | Carcinosarcoma,Endometrioid Adenocarcinoma,Endometrial Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07793578Phase 1/Phase 2 · not yet recruiting Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer · 55 trials list this drug (31 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05593497Phase 2 · recruiting A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04862663Phase 3 · active not recruiting Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06635447Phase 3 · active not recruiting Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients · 55 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04812366Phase 2 · recruiting Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer · 55 trials list this drug (31 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07281833Phase 3 · recruiting Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment · 55 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm,Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742102Phase 1/Phase 2 · active not recruiting A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer · 55 trials list this drug (31 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04556773Phase 1 · active not recruiting A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer · 55 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07426822Phase 2 · recruiting Rash & Diarrhea Prophylaxis With Capivasertib · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07241065Phase 1 · completed A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02813135Phase 1/Phase 2 · recruiting European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors · 55 trials list this drug (31 active) | — | — | Childhood Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06764186Phase 3 · active not recruiting A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain · 55 trials list this drug (31 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05563220Phase 1/Phase 2 · active not recruiting Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer · 55 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05039801Phase 1 · recruiting IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors · 55 trials list this drug (31 active) | — | — | Malignant Solid Neoplasm,Melanoma,Chondrosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439123Phase 2 · active not recruiting Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) · 55 trials list this drug (31 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04305496Phase 3 · active not recruiting Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02664935Phase 2 · completed National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer · 55 trials list this drug (31 active) | — | — | Adenocarcinoma,Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07294677Phase 1/Phase 2 · recruiting CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL · 55 trials list this drug (31 active) | — | — | Leukemia,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07088913Phase 1 · completed A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03801369Phase 2 · terminated AMTEC IIT: Phase 2 Multiarm Study in TNBC · 55 trials list this drug (31 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06613516Phase 2 · withdrawn Effect of Capivasertib on ctDNA in ER Positive Breast Cancer · 55 trials list this drug (31 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03997123Phase 3 · active not recruiting Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC · 55 trials list this drug (31 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01992952Phase 1/Phase 2 · active not recruiting Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07175415Phase 1/Phase 2 · not yet recruiting HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies · 55 trials list this drug (31 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01226316Phase 1 · completed Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules · 55 trials list this drug (31 active) | — | — | Malignant Ovarian Neoplasm,Malignant Cervical Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06607757Phase 2 · recruiting Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02423603Phase 2 · completed PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer · 55 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05348577Phase 3 · active not recruiting Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) · 55 trials list this drug (31 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02299999Phase 2 · active not recruiting SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer · 55 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05008055Phase 2 · completed Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02338622Phase 1 · completed Trial of Olaparib in Combination With AZD5363 (ComPAKT) · 55 trials list this drug (31 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05720260Phase 2 · recruiting Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC · 55 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04958226Phase 1 · completed A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours · 55 trials list this drug (31 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02117167Phase 2 · completed SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03310541Phase 1 · completed AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations · 55 trials list this drug (31 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02576444Phase 2 · terminated OLAParib COmbinations · 55 trials list this drug (31 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04742036Phase 1 · completed Capivasertib China PK Study · 55 trials list this drug (31 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04087174Phase 1 · completed A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer · 55 trials list this drug (31 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04944771Phase 1 · completed Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants · 55 trials list this drug (31 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02121639Phase 1/Phase 2 · completed Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy · 55 trials list this drug (31 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04712396Phase 1 · completed A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02451956Phase 2 · completed Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy · 55 trials list this drug (31 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03182634Phase 2 · unknown The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial · 55 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02525068Phase 2 · unknown A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC · 55 trials list this drug (31 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02077569Phase 2 · completed AKT Inhibitor in Oestrogen Positive Breast Cancer · 55 trials list this drug (31 active) | — | — | Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01895946Phase 1 · completed Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability · 55 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01353781Phase 1 · completed Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies · 55 trials list this drug (31 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |